분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-05-06 19:19:03 , Hit : 1798
 Targeted drugs to tackle hepatitis C


But experts debate US screening recommendations.

Beth Mole 01 May 2013 Corrected:
03 May 2013
Article toolsPrint


John strains to recall the gap between learning that he had hepatitis C and deciding to get treated: it was either four years or five. His thinking is clouded by the combination of three drugs that he is taking to clear the infection. After the treatments’ other side effects set in — severe flu-like symptoms, depression and exhaustion — he took leave from his job as a chef in New York. John, whose name has been changed to protect his privacy, was at high risk of catching the virus, having once been addicted to crystal methamphetamine. But as a 51-year-old, he is also a baby boomer — a member of the generation born between 1945 and 1965 — millions of whom will face the disease and its sometimes harrowing treatment.

Better drugs are on the way. But the possibility of improved treatment is intensifying a debate about whether to screen a broad swathe of the US population for hepatitis C.


Last month, the pharmaceutical company Gilead, based in Foster City, California, submitted its hepatitis-C drug sofosbuvir to the US Food and Drug Administration for approval, after phase II trials showed a 100% success rate in a few patient groups when it was used in combination with existing drugs. Last week, the first phase III results showed similarly promising results (E. Lawitz et al. N. Engl. J. Med. http://doi.org/mcc; 2013).

The drug is one of at least ten in phase III trials in the United States that promise to improve results or reduce side effects. The first of these drugs could reach the market as early as 2014, and a recommendation from the US Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, to screen an entire generation for the disease could create vast demand for them.

John is a part of a demographic time bomb. Up to 4 million Americans are infected with hepatitis C, which can irreparably damage the liver and lead to liver cancer, but because it inflicts injury slowly over decades, as many as 85% of carriers do not know that they have it. Baby boomers account for about 27% of the US population, but up to 75% of those infected with hepatitis C, possibly because injecting drugs — one infection route — was more common during their youth than in other eras. Last August, the CDC recommended screening the entire generation of people born between 1945 and 1965, as well as people in high-risk populations such as intravenous-drug users. The CDC predicts that generational screening would find an extra 800,000 cases and prevent at least 120,000 deaths. “We have an opportunity to make a real dent in the impact of the disease,” says Kimberly Page, an epidemiologist at the University of California, San Francisco.


ExpandSource: G. L. Davis et al. Gastroenterology 138, 513–521 (2010)
John’s doctor, infectious-disease specialist Kristen Marks of Weill Cornell Medical College in New York, says that screening is especially important for baby boomers because early symptoms of hepatitis C, such as fatigue and malaise, are difficult to distinguish from signs of ageing. People dismiss symptoms, says Marks, and some might not remember trying intravenous drugs in their youth. Even if they do, she adds, “they might not tell their doctor”. A peak in cases of liver scarring from untreated hepatitis C is expected in the next few years (see ‘An approaching burden’). But with the new drugs on the horizon, now is an optimistic time for treatment, says Marks. “Historically, not having good treatments was a disincentive for screening,” she says. “Now, I think there’s a renewed interest.”

But last November, the US Preventive Services Task Force (USPSTF), a panel of experts assembled by the US Department of Health and Human Services, released a draft statement giving the screening recommendation a ‘grade C’. That means that doctors should consider birth year when deciding whether to offer screening, but should take other factors into account. The mediocre grade could discourage many health-care providers — including Medicaid, the provider for people with low incomes — from pushing screenings.

As with its controversial recommendations in 2009 and 2012 to limit screening for breast and prostrate cancer, the USPSTF has tried to balance the benefits of screening against the risk of unnecessary treatment. The combination therapies used to combat hepatitis C can cost US$1,100 per week and last for up to a year, with severe side effects. Other treatments cost $4,100 per week. (Gilead declined to comment on the future price of sofosbuvir-based treatments.)

“We have an opportunity to make a real dent in the impact of the disease.”
Roger Chou, an internal-medicine specialist at Oregon Health and Science University in Portland and a scientific reviewer for the USPSTF, adds that in most patients, the disease is imperceptible: only 20% of people develop liver scarring in the first 20 years of infection, according to the CDC. Of the few baby boomers that might be caught through additional screening, says Chou, some will not need to be treated.

But new drugs, however expensive, could change the calculus for doctors and patients, says Mark Eckman, a physician at the University of Cincinnati in Ohio, who has calculated that even screening the entire US population would be cost effective given the financial and personal burdens of living with liver diseases (M. H. Eckman et al. Clin. Infect. Dis. 56, 1382–1393; 2013).

For example, sofosbuvir, which is one of a set of new antiviral drugs that specifically target hepatitis C rather than viruses in general, can achieve success rates above 90% in combination treatments of just three months. The drug inhibits the virus’s RNA polymerase, preventing viral replication. It is also being tested without the classic combination drug of pegylated interferon, which boosts the immune system but causes harsh side effects.

The USPSTF is still reviewing its draft recommendations, but it is likely to make a final decision in the next few months, well before approval of sofosbuvir or other new drugs could alter the calculations.

That is too bad, says David Thomas, a viral-hepatitis specialist at Johns Hopkins University in Baltimore, Maryland, who argues that the next generation of drugs helps to justify wide-scale screening. “It makes a pretty easy case for doing something different,” he says.

Journal name:
Nature
Volume:
497,
Pages:
18–19
Date published:
(02 May 2013)
DOI:
doi:10.1038/497018a







727   임자 있는 초원들쥐가 외간들쥐를 거들떠보지도 않는 이유: 후성유전학  이성욱 2013/06/05 3279
726   면역시스템이 유익세균과 평화로운 공존을 유지하는 방법  이성욱 2013/05/28 2492
725   TNF를 이용한 안전한 항종양 치료법  이성욱 2013/05/28 2656
724   Viruses in the gut protect from infection  이성욱 2013/05/22 2907
723   황우석을 넘어서: 미국의 과학자들, 체세포복제 기술로 인간 배아줄기세포 제조 성공  이성욱 2013/05/17 2462
722   Janssen's experimental drug for hepatitis C gets FDA fast track  이성욱 2013/05/15 2828
721   세상을 바꿀 10가지 기술  이성욱 2013/05/13 2330
720   Most Europeans share recent ancestors  이성욱 2013/05/10 2156
719   약물 저항성 세균을 파괴하는 방법  이성욱 2013/05/10 2552
718   분자생물학의 거성(巨星) 떨어지다; 프랑수아 자콥의 삶과 업적  이성욱 2013/05/09 2833
717   FDA fast tracks AbbVie hepatitis C drug  이성욱 2013/05/08 2196
  Targeted drugs to tackle hepatitis C  이성욱 2013/05/06 1798
715   DNA: Celebrate the unknowns  이성욱 2013/04/26 1972
714   Hepatitis C drug nears approval  이성욱 2013/04/24 2121
713   텔로머레이즈를 표적으로 삼는 새로운 항암 요법  이성욱 2013/04/24 3107
712   A pathogenic picornavirus acquires an envelope by hijacking cellular membranes  이성욱 2013/04/23 3003
711   BMS, Santaris Make Potentially $100M+ mRNA-Targeting Deal  이성욱 2013/04/17 2148
710   Scientists Map Elusive 3-D Structure of Telomerase Enzyme, Key Actor in Cancer, Aging  이성욱 2013/04/17 2305
709   Gilead seeks FDA OK for game-changing hepatitis C drug  이성욱 2013/04/10 2115
708   'RNA sponge' mechanism may cause ALS/FTD neurodegeneration  이성욱 2013/04/02 2605

[이전 10개] [1]..[21][22][23][24][25][26][27] 28 [29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN